his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
